Alvotech (ALVO NASDAQ) stock market data APIs
$9.6666
0.53(5.5%)
as of May 9, 2025
Try our APIs with
free plan!
Alvotech Financial Data Overview
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product for the treatment of adult patients with moderate to severe ulcerative colitis and moderate to severely active Crohn's disease; AVT23, a biosimilar to Xolair to treat allergic asthma, chronic spontaneous urticaria (CSU), and nasal polyp; and AVT33, a biosimilar to Keytruda product which is in early phase development. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.
Prev. Close
9.6666
Open
10.1943
High
10.3796
Low
9.6791
52 wk Range
7.9-10.4
Market Cap
2 921 M
Shares Outstanding
302 M
Revenue
492 M
EPS
-0.24
Beta
-0.022
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Alvotech data using free add-ons & libraries
Get Alvotech Fundamental Data
{
"General": {
"Code": "ALVO",
"Type": "Common Stock",
"Name": "Alvotech",
"Exchange": "NASDAQ",
"CurrencyCode": "USD",
"CurrencyName": "US Dollar",
"CurrencySymbol": "$",
"CountryName": "USA",
"CountryISO": "US",
"OpenFigi": "BBG014MBMZY2",
"ISIN": "LU2458332611",
"CUSIP": null,
"CIK": "0001898416",
"EmployerIdNumber": null,
"FiscalYearEnd": "December",
"IPODate": "2022-06-16",
"InternationalDomestic": null,
"Sector": "Healthcare",
"Industry": "Drug Manufacturers - Specialty & Generic",
"HomeCategory": null,
"IsDelisted": false,
"Description": "Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimila..."
}
}Alvotech Fundamental data includes:
- Net Revenue: 492 M
- EBITDA: 87 577 K
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-03-27
- EPS/Forecast: -0.0273
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Alvotech News
New
Analyst Estimates: Here's What Brokers Think Of Alvotech (NASDAQ:ALVO) After Its First-Quarter Report
It's been a pretty great week for Alvotech (NASDAQ:ALVO) shareholders, with its shares surging 18% to US$9.68 in the week since its latest quarterly results. Revenues came in at US$133m, an impressive...
Alvotech Meets Investors and Participates in Fireside Chat At the BofA Securities Healthcare Conference 2025 in Las Vegas, Nevada
Alvotech REYKJAVIK, Iceland, May 09, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients wo...
Alvotech Publishes Prospectus in Connection with its Listing on Nasdaq Stockholm
Alvotech Not to be released, published, distributed or circulated in the United States or any other jurisdiction in which it would be unlawful to do so. This press release is for information purposes...
Alvotech birtir uppgjör fyrir fyrsta ársfjórðung 2025 og kynnir nýjustu áfanga í rekstri félagsins
Heildartekjur á fyrsta fjórðungi ársins voru 132,8 milljónir dollara, samanborið við 36,9 milljónir á sama fjórðungi í fyrra, sem er 260% aukning Sölutekjur á fyrsta fjórðungi ársins...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
